ES2190095T3 - Sales nitricas de inhibidores del enzima de conversion. - Google Patents

Sales nitricas de inhibidores del enzima de conversion.

Info

Publication number
ES2190095T3
ES2190095T3 ES98938668T ES98938668T ES2190095T3 ES 2190095 T3 ES2190095 T3 ES 2190095T3 ES 98938668 T ES98938668 T ES 98938668T ES 98938668 T ES98938668 T ES 98938668T ES 2190095 T3 ES2190095 T3 ES 2190095T3
Authority
ES
Spain
Prior art keywords
formula
forms
riv
riii
enzyme inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98938668T
Other languages
English (en)
Inventor
Soldato Piero Del
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox SA
Original Assignee
Nicox SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox SA filed Critical Nicox SA
Application granted granted Critical
Publication of ES2190095T3 publication Critical patent/ES2190095T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0217Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -C(=O)-C-N-C(=O)-N-C-C(=O)-
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Sales nítricas de inhibidores de ACE que presentan las siguientes fórmulas: **(Fórmula)** en la fórmula (I) **(Fórmula)** O-N-CH3; Y=CH3, fenilo; R3=H; R3 junto con RIV forma el siguiente anillo en el carbono en la posición 4: **(Fórmula)** RIII junto con RV (carbonos en las posiciones 4 y 5) forma los anillos de ciclohexano o ciclopentano: **(Fórmula)** RIV = H, o RIV for ma con RIII el anillo (IVa); RV = H, o una valencia libre o RV forma con los RIII anillos (IIIa) o (IIIb); RVi = H, o un enlace simple -O, cuando RV es una valencia libre para formar un grupo cetona con un átomo de carbono en la posición 5.
ES98938668T 1997-06-27 1998-06-24 Sales nitricas de inhibidores del enzima de conversion. Expired - Lifetime ES2190095T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97MI001523A IT1292426B1 (it) 1997-06-27 1997-06-27 Sali nitrati di ace-inibitori

Publications (1)

Publication Number Publication Date
ES2190095T3 true ES2190095T3 (es) 2003-07-16

Family

ID=11377450

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98938668T Expired - Lifetime ES2190095T3 (es) 1997-06-27 1998-06-24 Sales nitricas de inhibidores del enzima de conversion.

Country Status (17)

Country Link
US (1) US6218417B1 (es)
EP (1) EP1019370B1 (es)
JP (1) JP2002506456A (es)
KR (1) KR100512892B1 (es)
CN (1) CN1205186C (es)
AT (1) ATE230393T1 (es)
AU (1) AU740411B2 (es)
BR (1) BR9810459A (es)
CA (1) CA2292794A1 (es)
DE (1) DE69810498T2 (es)
DK (1) DK1019370T3 (es)
ES (1) ES2190095T3 (es)
HU (1) HUP0003133A3 (es)
IL (1) IL132691A (es)
IT (1) IT1292426B1 (es)
RU (1) RU2194037C2 (es)
WO (1) WO1999000361A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1301759B1 (it) * 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
IT1303672B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
CA2383974A1 (en) 1999-09-08 2001-03-15 Nitromed Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US7537785B2 (en) 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
EP1244455B1 (en) 1999-10-29 2009-07-22 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7235237B2 (en) 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7708989B2 (en) * 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
EP1406608B1 (en) 2001-05-02 2009-07-29 Nitromed, Inc. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
CN1646140A (zh) * 2002-02-04 2005-07-27 阿尔法玛药品研发有限公司 可释放co的化合物在用于治疗炎症药物的制备中的应用
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
EP1562975A2 (en) * 2002-10-25 2005-08-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US7169805B2 (en) * 2003-05-28 2007-01-30 Nicox S.A. Captopril derivatives
AU2005274763A1 (en) * 2004-07-16 2006-02-23 Nitromed, Inc. Compositions and methods related to heart failure
CN101010323B (zh) 2004-08-25 2010-06-16 埃科特莱茵药品有限公司 作为肾素抑制剂的双环壬烯衍生物
SI1679072T1 (sl) * 2005-01-06 2009-02-28 Ipca Lab Ltd Postopek za sintezo derivatov (2S,3aS,7aS)-1-(S)-alanil-oktahidro-1H-indol-2-karboksilne kisline inuporaba v sintezi perindoprila
EP1883412A4 (en) * 2005-05-05 2008-09-03 Keryx Biopharmaceuticals Inc COMBINATION THERAPY WITH SULODEXIDE AND A BLOOD PRESSURE WRITING AGENT IN THE TREATMENT OF DIABETIC NEPHROPATHY
EP1893578A2 (en) * 2005-05-27 2008-03-05 Actelion Pharmaceuticals Ltd. Novel piperidine carboxylic acid amide derivatives
CA2626568A1 (en) * 2005-10-18 2007-04-26 Nicox S.A. Renin inhibitors nitroderivatives
WO2007073226A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda Method for treating a mammal by administration of a compound having the ability to release co
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
NZ570828A (en) 2006-02-02 2011-07-29 Actelion Pharmaceuticals Ltd Secondary amines as renin inhibitors
AU2007217980A1 (en) * 2006-02-17 2007-08-30 Nitromed, Inc. Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
CL2007000595A1 (es) * 2006-03-08 2008-01-04 Actelion Pharmaceuticals Ltd Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
CA2652135A1 (en) * 2006-05-16 2007-11-29 Nitromed, Inc. Solid dosage formulations of hydralazine compounds
WO2009135299A1 (en) 2008-05-05 2009-11-12 Merck Frosst Canada Ltd. 3, 4 - substituted piperidine derivatives as renin inhibitors
ES2656237T3 (es) 2011-04-19 2018-02-26 Alfama, Inc. Moléculas liberadoras de monóxido de carbono y usos de las mismas
JP6134710B2 (ja) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドAlfama,Inc. 一酸化ルテニウム放出分子およびその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5328933A (en) 1992-10-28 1994-07-12 Allergan, Inc. Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues
AU702662B2 (en) 1994-05-10 1999-02-25 Nicox S.A. Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities
US5625083A (en) 1995-06-02 1997-04-29 Bezuglov; Vladimir V. Dinitroglycerol esters of unsaturated fatty acids and prostaglandins
US5645839A (en) * 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
CN1141771A (zh) * 1995-08-02 1997-02-05 贾力 巯-亚硝基化合物及其医学用途

Also Published As

Publication number Publication date
RU2194037C2 (ru) 2002-12-10
JP2002506456A (ja) 2002-02-26
ATE230393T1 (de) 2003-01-15
EP1019370B1 (en) 2003-01-02
HUP0003133A3 (en) 2002-10-28
BR9810459A (pt) 2006-10-03
IL132691A (en) 2004-06-01
WO1999000361A1 (en) 1999-01-07
IL132691A0 (en) 2001-03-19
ITMI971523A1 (it) 1998-12-27
ITMI971523A0 (es) 1997-06-27
CN1205186C (zh) 2005-06-08
KR20010013958A (ko) 2001-02-26
US6218417B1 (en) 2001-04-17
DK1019370T3 (da) 2003-05-05
AU740411B2 (en) 2001-11-01
CA2292794A1 (en) 1999-01-07
IT1292426B1 (it) 1999-02-08
KR100512892B1 (ko) 2005-09-07
CN1260780A (zh) 2000-07-19
EP1019370A1 (en) 2000-07-19
HUP0003133A2 (en) 2001-03-28
DE69810498D1 (de) 2003-02-06
DE69810498T2 (de) 2003-10-30
AU8730098A (en) 1999-01-19

Similar Documents

Publication Publication Date Title
ES2190095T3 (es) Sales nitricas de inhibidores del enzima de conversion.
ES2130985B1 (es) Hidroxifeniltriazinas.
TW370450B (en) Substituted 1H-3-aryl-pyrrolidine-2,4-dione derivatives
UY24819A1 (es) Nuevos compuestos
ES2145115T3 (es) Composiciones inyectables a base de derivados de taxanos.
GT199900056A (es) Nuevas dihidropirimidinas
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
DK0679154T3 (da) Ny krystallinsk form af en d-vitamininanalog
UY27338A1 (es) Nuevos derivados de ácido sulfónico
ES2159347T3 (es) Naftil-acetamidas como inhibidores de spla2.
BR9806321A (pt) Processo e composição para inibir a polimerização durante a produção anaeróbica de estireno.
MX9303742A (es) Derivados de 4-hidroxi-bencentio, procedimientp para su preparacion y su empleo para la preparacion de derivados de amonoalcoxibencensulfonilos.
DK0734380T3 (da) 4-Benzoylisoxazoler samt deres anvendelse som herbicider
CO5080754A1 (es) Caspasas y apoptosis
ES2172967T3 (es) Metilciclotetradec-5-en-1-ona.
AR241534A1 (es) Compuestos de 7-(2-(5-amino-1,2,4-tiazol-3-il)-2-alcoxiimino-acetamido)-3-metil-imidazo piridinio o imidazo-pirimidinio-3-cefem-4-carboxilato y sus sales.
CO4970804A1 (es) Nuevos derivados de la vitamina d3
GT199900084A (es) Derivados de 3-(2-oxo-[1,3']bipirrolidinil-3-ilidenemetilo)-cefems.
ES2060592T3 (es) Un tioester y su uso en la preparacion de composiciones farmaceuticas para el tratamiento de los sindromes de isquemia y reperfusion.
ES2108897T3 (es) Compuesto del tipo oxima eter, procesos para su preparacion y fungicida que contiene dicho compuesto.
ES2189736T3 (es) Derivados de la benzamida y medicamentos que los contienen.
AR241590A1 (es) Procedimiento para elaborar 1-fenil-3-azabiciclo(3.1.0)hexan-2,4-dionas y sus sales.
CO4410199A1 (es) Procedimiento estereoselectivo para producir derivados de dihidro-2,3-benzodiacepina
TR200402432T4 (tr) Benzoksa-ve benzotiazolil sülfamat'lar ve bunların steroid süllfataz inhibitörler olarak kullanımı
CO5040081A1 (es) Nuevos compuestos vidad farmaaceutica